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Abstract
Backround: The number of cancer survivors is growing steadily and increasingly, clinical trials are being designed
to include long-term follow-up to assess not only survival, but also late effects and health-related quality of life
(HRQOL). Therefore it is is essential to develop patient-reported outcome measures (PROMs) that capture the full
range of issues relevant to disease-free cancer survivors. The objectives of this project are: 1) to develop a European
Organisation for Research and Treatment of Cancer (EORTC) questionnaire that captures the full range of physical,
mental and social HRQOL issues relevant to disease-free cancer survivors; and 2) to determine at which minimal
time since completion of treatment the questionnaire should be used.
Methods: We reviewed 134 publications on cancer survivorship and interviewed 117 disease-free cancer survivors
with 11 different types of cancer across 14 countries in Europe to generate an exhaustive, provisional list of HRQOL
issues relevant to cancer survivors. The resulting issue list, the EORTC core questionnaire (QLQ-C30), and site-specific
questionnaire modules were completed by a second group of 458 survivors.
Results: We identified 116 generic survivorship issues. These issues covered body image, cognitive functioning,
health behaviors, negative and positive outlook, health distress, mental health, fatigue, sleep problems, physical
functioning, pain, several physical symptoms, social functioning, and sexual problems. Patients rated most of the
acute symptoms of cancer and its treatment (e.g. nausea) as no longer relevant approximately one year after
completion of treatment.
Conclusions: Compared to existing cancer survivorship questionnaires, our findings underscore the relevance of
assessing issues related to chronic physical side effects of treatment such as neuropathy and joint pain. We will
further develop a core survivorship questionnaire and three site-specific modules for disease-free adult cancer
survivors who are at least one year post-treatment.
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Background
With continuing improvement in early detection and
treatment, and an aging population, the number of can-
cer survivors is increasing steadily. This has resulted in a
growing interest in evaluating the health-related quality
of life (HRQOL) of cancer survivors [1]. Increasingly,
clinical trials and comparative effectiveness studies are
being designed to include long-term follow-up to assess,
in addition to survival, late effects of treatment and
HRQOL. In order to integrate HRQOL in such studies,
it is essential to develop patient-reported outcome mea-
sures (PROMs) that capture the full range of issues rele-
vant to disease-free cancer survivors.
Many of the cancer-related HRQOL questionnaires that
are available today, including the European Organisation
for Research and Treatment of Cancer core questionnaire
(EORTC QLQ-C30) [2] and the Functional Assessment of
Cancer Therapy – General (FACT-G) [3], with their
supplementary site-specific modules, may not be entirely
appropriate for assessing the experiences of disease-free
cancer survivors. These questionnaires include items asses-
sing acute and treatment-related symptoms (e.g., vomiting)
that are typically no longer relevant in the post-treatment
survivorship period. Conversely, they may not adequately
address physical and psychosocial health problems particu-
larly relevant to cancer survivors (e.g., fear of recurrence,
return to work).
Questionnaires that have been developed specifically for
use among (long-term) cancer survivors include the Cancer
Problems in Living Scale (CPILS) [4, 5], Impact of Cancer
(IOC/IOCv2) [6–8], Quality of Life in Adult Cancer
Survivors (QLACS) [9, 10], Quality of Life Cancer
Survivors (QoL-CS) [11] and Satisfaction with Life
Domains Scale for Cancer (SLDS-C) [12]. These ques-
tionnaires focus primarily on psychosocial aspects of
survivorship and pay relatively little attention to asses-
sing chronic physical effects of cancer and its treatment
[13]. Additionally, while they assess generic (e.g., fear of
recurrence) HRQOL issues relevant to the survivorship
period, these questionnaires do not include condition-
specific issues which may persist or arise as a long-term
consequence of treatment (e.g., genitourinary problems
in prostate cancer survivors or lymphedema problems
in breast cancer survivors). Also, they often have been
based on investigations of a limited number of cancer
sites and on survivors living in the United States [4–8,
12], thus limiting their generalizability to other survivor
populations in other countries. Finally, for most of
these questionnaires, there is only limited information
available about their psychometric properties, or the
psychometrics have been based on only a small number
of cancer survivor populations [13].
For this reason, the EORTC Quality of Life Group
(QLG) has embarked on a project with the primary
objective of developing a HRQOL assessment approach
that captures the full range of issues relevant to disease-
free cancer survivors, both in general and for specific
cancer sites. Many definitions of cancer survivorship
have been used in the literature [14]. We use the term
“cancer survivor” to describe any person who has been
diagnosed with cancer who has completed treatment
with curative-intent (with the exception of maintenance
treatment) and is disease-free (no evidence of active
cancer). Since The EORTC QLG’s current portfolio of
measures has been primarily designed to assess patients’
HRQOL during treatment and shortly after completion
of treatment, it makes sense to begin use of survivorship
measures once the acute symptoms of the disease and
its treatment have resolved. An important secondary
objective of this project is to determine the most appro-
priate minimum time since end of primary treatment for
commencing use of survivorship HRQOL measures.
The conceptual framework we employed for the devel-
opment of the questionnaire followed the World Health
Organization (WHO) definition of health, dating from
1948, as “a state of complete physical, mental, and social
well-being and not merely the absence of disease or infirm-
ity”. Combined with the Medical Outcomes study (MOS)
framework it delineates three key dimensions of health:
physical, mental and social [15]. These three dimensions
can be assessed by several types of indicators (see Fig. 1).
Some of these indicators reflect primarily one of the three
dimensions (e.g., physical functioning) and others reflect
two or three dimensions (e.g., fatigue) [15].
In terms of measurement strategy, this project follows
the tradition within the EORTC QLG of involving patients
from a range of countries, cultures and languages at every
step in the developmental process. Additionally, given the
goal of addressing both generic and cancer site-specific
survivorship issues, the project encompasses a broad
range of diagnostic groups. We follow the EORTC QLG’s
four- phase process of questionnaire development [16]: 1)
generation of relevant HRQOL of issues; 2) conversion of
HRQOL issues into a set of questionnaire items; 3) ques-
tionnaire pre-testing; and 4) large-scale international field
testing. In the current paper we report on the results of
the first phase of this project.
Methods
Phase I had two aims: 1) to determine the full range of
issues relevant to disease-free cancer survivors, both in
general and for specific cancer sites; and 2) to determine
the most appropriate minimum time since end of pri-
mary treatment for commencing use of survivorship
HRQOL measures. It consisted of two sub-phases: In
phase 1a we generated an exhaustive list of HRQOL is-
sues, drawing upon two primary sources: the literature
and cancer survivors. In phase 1b we asked a sample of
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cancer survivors to rate the QLQ-C30 to determine at
which time after treatment completion the acute symp-
toms and side-effects related to cancer and its treatment
are no longer relevant. We considered the diminishing
prevalence of these symptoms an indicative of the need
to shift to the assessment of longer term survivorship is-
sues. In addition, the survivors participating in phase 1b
rated the list of HRQOL issues developed in phase 1a to
identify the issues relevant to disease free-survivors. In
this phase only quantitative data analyses were applied.
The workflow of the study is also presented in Fig. 2.
Literature search
In October 2014, we performed a literature search in
PubMed and PsycINFO, the goal of which was to identify
the full range of HRQOL issues relevant to all adult disease-
free cancer survivors, irrespective of their specific diagnosis.
We used the following search terms: (“Survivors”[Major]
OR “Survivors/psychology”[Major]) AND (“neoplasms”[Ma-
jor] OR “Carcinoma”[Major]) AND (“Quality of Life”[Mesh]
OR “patient-reported outcomes” OR “health-related quality
of life” OR “wellbeing” OR “well-being” OR “Mental
Health”[Major] OR “Physical Fitness/psychology”[Major]
OR “Physical Fitness/physiology”[Major] OR “Health Sta-
tus”[Major] OR “late effects”) AND adults. We included
only original articles published in English that investigated
HRQOL in adult, disease-free cancer survivors. Articles
reporting only scale scores without reference to specific sur-
vivorship issues were excluded. Two of the authors (MVL
and OH) screened references independently, and disagree-
ments were resolved by consensus.
Study sample
For phase 1a & b we recruited cancer survivors from hos-
pitals from four geographic regions: the United Kingdom,
Northern Europe (Denmark, Germany, the Netherlands,
Norway, Sweden), Southern Europe (Cyprus, France,
Greece, Israel, Italy, Spain), and Central Europe (Austria,
Poland). Inclusion of participants for phase 1b took place
after completion of phase 1a. Eligible patients were those
aged 18 years or older at the time of diagnosis who had
sufficient command of their native language and did not
have severe psychological or cognitive problems.
Fig. 1 Three-dimensional theoretical framework of health. In this framework health is assessed by multiple health indicators
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To ensure that the survivorship questionnaire would
be generic in nature, we recruited survivors with a range
of cancer diagnoses, selected on the basis of their preva-
lence and/or survival rates. This included 11 diagnoses:
breast, colorectal, prostate, bladder, gynecological (ovar-
ian, cervix and endometrial), head and neck, lung, and
testicular cancer, lymphoma, melanoma, and glioma. Eli-
gible patients had completed their treatment with cura-
tive intent (both primary treatment and treatment of
recurrent disease) at least 6 months earlier and were
disease-free (no evidence of disease). They could be re-
ceiving maintenance therapies (e.g., hormonal treatment
for primary breast cancer). Although low-grade glioma
patients are not treated with curative intent and are not
disease-free, they were included in the study because
they have a median survival of between 4.7 and 9.8 years
[17]. We employed purposive sampling to ensure an
approximately equal distribution of patients across diag-
noses and time since treatment (see below).
Basic sociodemographic data collected at study entry
included: age, sex, education, employment status, and
living arrangement. Clinical data collected included pri-
mary diagnosis, stage of disease, type of treatment, date
of diagnosis, date of start of primary treatment, date of
completing primary treatment, recurrences, date of com-
pletion of treatment for last recurrence, and comorbidity
using the Charlson Index [18].
Phase 1a survivor interviews: issue generation
We conducted semi-structured interviews with an initial
sample of survivors in order to generate an exhaustive
list of relevant HRQOL issues. The goal was to complete
10 interviews per diagnostic group, equally distributed
over the four geographical regions [16]. First, the
Fig. 2 Work flow of phase I. TST time since completing last treatment
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respondents were asked open-ended questions about
their survivorship experience. Subsequently, respondents
were shown the EORTC core questionnaire (QLQ-C30)
and, if available, the relevant site-specific questionnaire
module [19–32]. These cancer site-specific modules
assess the HRQOL issues most relevant to each of the
specific patient populations. These modules range in
length from 13 to 35 items. Instead of completing these
questionnaires, the respondents were asked to rate the
relevance of the items on a 4-point scale (not at all, a
little bit, quite a bit, or very relevant). The respondents
were also asked to identify survivorship issues that they
believed to be important that were not included in the
QLQ-C30 and, where relevant, site-specific module.
Relevance ratings of the EORTC core questionnaire
(QLQ-C30)
We evaluated the relevance ratings by composing scales
that were in accordance with the QLQ-C30 scale structure:
5 multi-item functioning scales (physical, role, emo-
tional, cognitive, and social functioning), three multi-
item symptom scales (fatigue, pain, nausea/vomiting),
and 6 single items (dyspnea, insomnia, appetite loss,
constipation, diarrhea, and financial difficulties). All
scores were linearly transformed to a 0 to 100-points
scale. A higher score on a scale means that the survi-
vors considered the items of this particular scale more
relevant. We compared the following survivor groups:
0.5 to 2 years since diagnosis, 2 to 5 years since diag-
nosis, and 5 years or more since diagnosis.
Issue extraction from literature and interviews
Phase 1a interviews were transcribed and translated in
English by the interviewers. We employed thematic ana-
lysis [33] using NVivo 10 [34], a software program for
qualitative data analyses, to extract a list of relevant sur-
vivorship issues from the articles included in the literature
review and from the transcribed semi-structured phase 1a
interviews. Literature and interviews were analyzed simul-
taneously using the coding system that evolved during the
thematic analyses. Items of the existing questionnaires
and the issues described in the qualitative studies were
coded in issues that were organized into hierarchical trees.
Cancer site or sex-specific issues were extracted in separ-
ate coding trees, and kept separately to avoid survivors in
phase 1b having to rate too many issues. All issues were
consolidated into a provisional list which included generic,
site-specific, and sex-specific issues to be completed by a
second group of survivors in phase 1b.
Phase 1b survivor interviews: defining minimal time since
treatment completion and issue selection
In the second round of interviews, our goal was to recruit
330 survivors: 10 interviews per survivor group * 11
diagnostic groups * 3 time periods (6 months – 2 years /
2–5 years / > 5 years since completing primary treatment)
[16]. The sample was also stratified according to geograph-
ical region. The respondents were asked to complete the
provisional issue lists, using a 4-point response scale (not at
all, a little bit, quite a bit, or very much) to indicate the
extent to which they had experienced each issue. The
provisional issue lists consisted of a generic survivor issue
list, and the sex- and cancer site-specific issues. In addition,
they were also asked to complete the QLQ-C30 and, if
available, the relevant site-specific module using the
same response scale. This was followed by a debrief-
ing interview about any relevant issues missing from
the provisional issue lists.
Definition of the minimal time since end of treatment for
assessing survivorship issues
To determine the minimum time since end of treatment
for which the survivorship questionnaire would be rele-
vant, we divided the Phase 1b sample into three time-
since-completion-of-last-treatment (TST) groups: (1) 0.5
to 1 years; (2) 1 to 2 years; and (3) 2 years or more since
treatment completion. For each TST group we investi-
gated which items of the QLQ-C30 were rated as rele-
vant for that specific group: an item was considered
relevant if at least 30% of the respondents in a group
endorsed an item (i.e., had experienced the issue at least
“a little bit”). We were particularly interested in compar-
ing responses to the QLQ-C30 items between the three
TST groups, as the QLQ-C30 contains a number of
acute symptom and side-effect items. Our objective here
was to determine at what point in time these relatively
acute issues were no longer relevant for the majority of
respondents, and thus it would be appropriate to begin
using survivorship measures.
Criteria for issue selection in phase 1b
In this phase, the provisional issue list was reviewed to
generate one comprehensive list of generic issues that
was relevant to all groups of cancer survivors, regardless
of specific diagnosis. In addition, site-specific issue lists
and sex-specific issues were generated. As indicated
above, we coded an issue as being endorsed by a re-
spondent if it was scored “a little bit” or higher. An issue
needed to be endorsed by at least 30% of the survivors
in any given diagnostic group to be regarded as an issue
relevant to that group. If an issue was endorsed by survi-
vors from 6 or more diagnostic groups, it was then con-
sidered to be a generic survivorship issue; otherwise it
was deemed to be a cancer-site specific issue. This
resulted in 12 consolidated survivorship issue lists: one
generic list and 11 cancer-site specific lists.
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Sub-analyses in the younger age groups
Previous research has shown that younger adult survi-
vors can be particularly impacted by the cancer experi-
ence [35–41]. For this reason, we performed post-hoc,
age-related subgroup analyses to identify issues that are
particularly relevant to survivors younger than 50 years.
We divided the total sample into five age groups (< 40;
40–50; 50–60; 60–70; 70+ years). Issues endorsed as
relevant by at least 30% of respondents under the age of
50 years that would otherwise have been excluded on
the basis of ratings by respondents above the age of 50
(i.e. low endorsement in the older sample causing the
endorsement in the total sample to be below 30%) were
retained in the generic list as being particularly relevant
for younger cancer survivors. Our expectation was that
we would retain issues likely to be specifically relevant
to younger cancer survivors such as problems in obtain-
ing a mortgage or family planning.
Results
Literature review
The literature search identified 1494 publications, of
which 134 were retained for issue extraction (for details
see Fig. 3). The list of 134 articles included in the review
can be found in Additional file 1. Research articles
included in the review were most commonly qualitative
studies, studies developing cancer survivor specific mea-
sures, or studies reporting the use of a self-constructed
study-specific measure.
Semi-structured interviews phase 1a: issue generation
For phase 1a, 117 survivors were interviewed between
August 2014 and May 2015 in nine different European
countries (Table 1). The average age of the survivors was
57 years (SD = 13.6 years), and 54% had received their
cancer diagnosis between 2 and 5 years ago.
Issue extraction from literature and interviews
In the first step, we identified 1555 issues from the 117
interviews and the first 75% of the research articles. These
issues were classified into 11 themes: mental health, phys-
ical symptoms, cognitive changes, role functioning (includ-
ing work), meaning of cancer, health behaviors, spirituality,
social functioning (including feelings of belonging), finan-
cial issues, body image, and sexuality. In the next step we
reduced this list to 718 issues by combining issues that
were very similar or formed a continuous scale (e.g. “de-
pression” and “feeling depressed” were combined into “feel-
ing depressed”). The remaining 25% of studies was coded
using this 718 issues coding system. We did not identify
new issues in these studies. In the last step, the total
number of issues was further reduced. Issues that were very
specific were combined. For example, “fear of recurrence
when having physical symptoms” and “fear of recurrence
around physical exams” were combined into “fear of recur-
rence”. Issues reflecting states like “being retired” were not
included, as they cannot be assessed on a 4-point scale, and
would not be informative for an assessment of HRQOL.
Issues stating a change in physical symptoms were not
included. General issues like “emotional problems” were
not included as we believed that they were better captured
by more informative issues, for example, “being worried”,
“fear of dying”, “anxiousness”, “feeling stressed”, “feeling
depressed”. This resulted in 197 generic, 62 cancer site-spe-
cific (e.g. pain during urination), and 8 sex-specific (e.g.
feeling less feminine) issues.
Relevance ratings of the EORTC core questionnaire
(QLQ-C30)
The relevance ratings are presented in Fig. 4. The figure
shows that the functioning scales were still considered
relevant by the survivors, with the perceived relevance
increasing with longer time since diagnosis. A number
of the symptom items and scales were considered less
relevant, especially when more time had passed since
diagnosis. Two years after diagnosis, nausea/ vomiting,
appetite loss, constipation, and diarrhoea were seldom
Fig. 3 Prisma flow chart of the literature review
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rated as being relevant. The ratings showed that particu-
larly insomnia was considered highly relevant by the
survivors less than 2 years after diagnosis and fatigue by
the survivors who were less than 5 years since diagnosis.
Phase 1b interviews: defining minimal time since
treatment completion and issue selection
Between November 2015 and August 2016, we inter-
viewed 458 survivors from 23 centers in 14 countries for
phase 1b (Table 1). The mean age of the sample was
59 years, and 46% was female. Sixty percent had been
diagnosed with stage I or II cancer, and 16% had experi-
enced disease recurrence in the past. The average time
since last treatment was 3.6 years (Table 2).
We started our analyses by defining the post-treatment
survivorship period in the complete phase 1b sample by
comparing the three subgroups (0.5–1 year, 1 to 2 years,
and 2 years or more post-treatment). The following QLQ-
C30 items were rated as being relevant in the 0.5–1 year
post-treatment survivors subgroup, but no longer so in
the other two TST subgroups: needing to stay in bed or a
chair during the day, pain interfering with daily activities,
physical condition or treatment interfering with family life
and social activities, and physical condition or treatment
causing financial difficulties. Scores on the functional and
symptom scales of the QLQ-C30 showed an increase in
physical, role emotional and social functioning one year
after completion of treatment, and a decrease in fatigue
(Fig. 5). After this first year these scores tended to
stabilize. Based on these findings we decided to
employ the one year post-treatment mark as the
threshold for recommending transitioning to the use
of survivorship measures.
Additionally, the analyses of the QLQ-C30 data
showed that the following items were of low relevance
to all of the TST survivor subgroups: “Do you have any
trouble taking a short walk outside of the house?”, “Do
you need help with eating, dressing, washing yourself or
using the toilet?”, and those items assessing appetite,
nausea, vomiting, and gastrointestinal symptoms.
For the subsequent selection of issues to be included
in the survivorship questionnaire, only the 386 respon-
dents who were at least 1 year post-treatment were
included. Table 3 displays the 116 issues that were re-
ported as being relevant by respondents in at least 6 of
the diagnostic groups. Thirty-four percent of these con-
sisted of issues covering physical functioning (e.g. pain,
neuropathy, muscle cramp), 32% were mental function-
ing issues (e.g. body image, anxiety, positive affect), 19%
issues were related to social and role functioning (e.g.
sexual problems, feelings of belonging) and 16% involved
general health perceptions (e.g. negative health outlook
and health behavior). Of the 116 issues, 106 were not
included in the QLQ-C30. Table 3 shows which issues
are overlapping with the QLQ-C30, which were identi-
fied from the literature, and which from the interviews.
In addition to generic issues, we also identified sur-
vivorship issues that were cancer site-specific. On
average, 26 (range 7–48) issues were considered as
cancer-site specific per diagnostic group. We intend to
use these issues for the future development of cancer
site-specific survivorship modules. Among these can-
cer site-specific survivorship issues, we observed the
following trends: body image issues were frequently
endorsed by bladder, breast, colorectal, and head &
neck cancer survivors. Cognitive functioning problems
were rated as highly relevant by glioma, lymphoma,
lung, bladder, breast, and head and & neck cancer
Table 1 Number of cancer survivors per cancer site and per
region included in phase 1a and 1b
Phase 1a Phase 1b
Cancer site
Bladder 7 32
Breast 17 53
Colorectal 12 46
Glioma 10 36
Gynecological 12 49
Head & neck 10 44
Lung 8 41
Lymphoma 9 38
Melanoma 11 38
Prostate 11 44
Testicular 10 37
Total 117 458
Region
Northern Europe 30 147
Southern Europe 46 126
English speaking 13 98
Central Europe 28 87
Time since diagnosis
0.5 to 2 years 21 111
2 to 5 years 63 189
more than 5 years 33 158
Time since completing last treatmenta
0.5 to 1 year – 72
1 to 2 years – 105
2 to 5 years – 172
more than 5 years – 109
For phase 1b only, also the number of survivors per time since completion of
last treatment category is reported
aFor phase 1a only information was available regarding date of diagnosis and
date of recurrence
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survivors. Lung cancer and glioma survivors reported
having a negative health outlook as highly relevant.
Bladder and head & neck cancer survivors frequently
endorsed role functioning issues. Lung, lymphoma,
and colorectal cancer survivors more often endorsed
work-related issues than the other survivor groups.
Glioma and lymphoma survivors more frequently
rated issues related to a negative impact on feelings of
belonging as relevant.
Based on the 94 survivors below the age of 50 years,
we identified 10 issues that were relevant for younger
survivors and for which relevance declined with age (see
Table 3). Three issues were related to body image; the
others were related to the ability to have children, being
treated differently by people because of having had can-
cer, difficulties talking about cancer, negative personality
change, needing psychological support, loss of future life
plans, and financial problems.
Discussion
In this first phase of our cancer survivorship questionnaire
development project, we identified 116 generic survivor-
ship issues. Additionally, on average, we identified 26
site-specific survivorship issues per tumor site, which only
partially overlapped with the existing EORTC site-specific
modules. We also observed that, approximately one year
following completion of cancer treatment, most of the
acute disease- and treatment-related symptoms have
resolved themselves in the large majority of survivors.
Based on these findings, we will move forward with
the development of a core survivorship questionnaire for
disease-free adult survivors who are at least one year
post-treatment. This questionnaire will retain many of
the original items and scales from the QLQ-C30, delet-
ing only those items that assess acute symptoms (nau-
sea/vomiting, appetite loss, constipation, and diarrhea).
Additional survivorship issues will be added to expand
Fig. 4 Relevance ratings of the functional and symptom scales of the QLQ-C30 per time since diagnosis group. The y-axis shows the relevance
ratings of the QLQ-C30. A higher score on a scale means that the survivors considered the items of a particular scale more relevant
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the scope of issues addressed by the questionnaire. To
improve the measurement precision of some of the
existing scales of the QLQ-C30, we will collaborate with
the EORTC CAT team [42] to select the issues of the
generic issue list and the items of the EORTC QLG item
library assessing these issues. This survivorship ques-
tionnaire can be complemented by cancer-site specific
survivorship modules based on and adapted from the
existing EORTC cancer site-specific modules.
The period after treatment completion is often de-
scribed by survivors as more difficult than the treatment
itself [43]. The end of the phase of transition from being a
patient to resuming normal life [44] can be very positive,
but also brings with it feelings of uncertainty about the
future and fear of cancer recurrence. During this early
survivorship period, patients often begin to process the
emotions related to the diagnosis, to find meaning in their
experience of having had cancer, and to deal with the
lingering effects of treatment. The end of this turbulent
immediate post-treatment period appears to represent an
appropriate starting point for assessing survivorship is-
sues, as both physical and psychosocial health begin to
stabilize. This was corroborated by the increase in phys-
ical, role, and social functioning and the decline in fatigue
observed in our study sample after the first post-treatment
year. We did not observe a further decline in the acute
symptoms of cancer treatment, as the prevalence of acute
symptoms was already low a half year after treatment
completion. The chronic side effects of treatment
(pain, dyspnea, insomnia, and fatigue) continued to be
relevant for all survivor groups into the longer post-
treatment phase.
In accordance with the existing cancer survivorship
questionnaires [4–12] our results indicate that feelings of
uncertainty about the future, fears related to recurrence of
cancer, fears and worries concerning family members,
feelings of depression and anger, feelings that others do
not understand the impact of cancer, positive impact on
social relationships, positive changes in (perception of)
Table 2 Basic demographics, disease and treatment characteristics
of the survivors included in phase 1b
Survivors Phase 1a Phase 1b
N = 117 Total
N = 458
Subsample
N = 386a
Age
Mean ± SD (years) 57 (13.6) 59 (13.8) 59 (13.7)
Sex (%)
male 58 (50%) 246 (54%) 207 (54%)
Partner statusb
in relationship 90 367 313
widower/ divorced/
separated
9 61 49
single 14 50 43
Education (%)
none or primary
school only
15 (13%) 59 (13%) 47 (12%)
high school 46 (39%) 167 (36%) 140 (36%)
college or university 53 (45%) 222 (48%) 190 (49%)
missing 3 (3%) 10 (2%) 9 (2%)
Work status (%)
working 59 (50%) 205 (45%) 180 (47%)
retired 43 (37%) 185 (40%) 157 (41%)
unemployed 4 (3%) 24 (5%) 17 (4%)
homemaker 4 (3%) 22 (5%) 17 (4%)
disabled 5 (4%) 10 (2%) 7 (2%)
other or missing 2 (2%) 12 (2%) 10 (3%)
Disease recurrence (%) 11 (9%) 75 (16%) 66 (17%)
Tumor stagec (%)
stage I 19 (16%) 101 (23%) 88 (24%)
stage II 45 (38%) 131 (30%) 108 (28%)
stage III 29 (25%) 113 (25%) 95 (25%)
stage IV 3 (3%) 40 (9%) 34 (9%)
stage unknown 13 (11%) 47 (11%) 40 (10%)
no stage determined 8 (7%)
Time since completing primary treatment
Mean (SD) (years) – 4.2 (4.0) 4.8 (4.0)
Time since completing last treatment
Mean (SD) (years) – 3.6 (3.2) 4.4 (3.2)
Therapyb
surgery 98 342 326
chemotherapy 77 254 222
radiotherapy 54 238 209
hormonal therapy 15 49 48
monoclonal antibodies 2 21 18
cell transplantation 6 6
active surveillance 7 66 59
Table 2 Basic demographics, disease and treatment characteristics
of the survivors included in phase 1b (Continued)
Survivors Phase 1a Phase 1b
N = 117 Total
N = 458
Subsample
N = 386a
current maintenance
therapy
8 61 47
Percentages are given in the cases that categories are mutually exclusive
N number, SD Standard deviation
asubsample of phase 1b that consists of the survivors who are at least 1 year
after treatment completion
bcategories are not mutual exclusive, e.g. one can be a widower and have a
new relationship
cfor glioma survivors in Phase 1b tumor grading was used, we included per
tumor grade: grade 1: 2 survivors; grade 2: 8 survivors; grade 3: 14 survivors;
grade 4: 1 survivor
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life, negative body image, cognitive problems, fatigue,
sleeping problems, pain, sexual problems, and dealing
with the chronic physical consequences of cancer are all
relevant issues for cancer survivors. However, our results
also indicate that other issues often included in survivor-
ship questionnaires may be less relevant when rated by a
wider range of cancer survivors in an international
context. This includes issues related to feelings of guilt,
fears related to starting new (romantic) relationships, and
feelings of pride about having survived cancer. Also,
compared to existing questionnaires, our findings under-
score the relevance of assessing issues related to chronic
side effects of treatment such as neuropathy and joint pain
[4–12]. Over 30% of the issues were related to physical
functioning, including chronic physical effects of cancer
and its treatment, like Raynaud symptoms, neuropathy,
joint pain, and muscle cramps. These issues receive rela-
tively little attention in the existing cancer survivorship
questionnaires. The differences between our findings and
the existing survivorship questionnaires may reflect both
culture (including differences between the American and
European health care systems) and the fact that we in-
cluded a wider range of diagnostic groups in our study,
and placed relatively less emphasis on breast cancer and
non-solid cancer survivors, as has typified the develop-
mental phase of other survivorship questionnaires.
Another important finding from our study is that there
is not only a fairly large number of condition-specific
physical health issues in cancer survivorship, but also
differences in the extent to which various psychosocial
issues are perceived as relevant by specific cancer diag-
nostic groups. These differences in perceived relevance
of survivorship issues may reflect differences in sur-
vival rates between the cancer types, the average age at
diagnosis, the nature of the chronic side effects of the
various treatments, and whether a cancer diagnosis is
sex-specific. For example, glioma and lung cancer sur-
vivors reported issues related to the negative impact of
Fig. 5 Functional and symptom scales of the QLQ-C30 per time since last treatment category. The y-axis shows the scores on QLQ-C30. On the
functional scales a higher score represents a better level of functioning and on the symptom scales a higher score represents a higher level
of symptoms
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Table 3 Consolidated issue list with generic survivorship issues
Body Image
• feeling unattractive b, c
• feeling oldb
• feeling satisfied with your physical appearanceb, c
• feeling you could not trust your bodyb, c
Cognitive functioning
• difficulties with concentrationa,b, c
• forgetfulnessb, c
• memory problemsa,b, c
• problems with multi-taskingb, c
• difficulty gathering your thoughts (together)b, c
• ability to think (to process information) has slowed downb, c
Health behaviors
• being alert for symptoms that may signal a return of my cancerb, c
• going quickly to my GP due to having (had) cancerc
• drinking less alcohol due to having (had) cancerb, c
• listening to my body due to having (had) cancerb, c
• eating healthily due to having (had) cancerb, c
• avoiding the sun or protecting my skin due to having (had) cancerb, c
• exercising (more) due to having (had) cancerb, c
• avoiding stress in my life due to having (had) cancerb, c
• cutting down smoking due to having (had) cancer (not applicable option)b, c
• taking better care of yourself due to having (had) cancerb, c
Meaning of cancer
• other issues not related to cancer bother me more than having had cancerb, c
• cancer is a learning experienceb, c
• having (had) cancer has made me accept my own mortalityb, c
• overall quality of lifea, b, c
• being (more) emotional due to having (had) cancerb, c
• seeking a deeper meaning in having (had) cancerb
Negative outlook
• concerned with long term effects of cancer treatmentb, c
• feeling that my life has been suspended because of having (had) cancerb, c
• difficulties adapting my life to the physical consequences of having had cancerb, c
• still feeling like a cancer patientb, c
• experiencing uncertainty about the futureb, c
Positive outlook
• appreciating life (more) due to having (had) cancerb, c
• being psychologically strong(er) due to having (had) cancerb, c
• my personality has changed for the better due to having (had) cancer b, c
• having (had) cancer has given me a purpose in lifeb
• because of having (had) cancer I have reconsidered my priorities in lifeb, c
• standing up for myself (more) due to having (had) cancerb, c
• having (had) cancer has given me a reason to make changes in my lifeb, c
• willing to help others (more) due to having (had) cancerb, c
• due to having (had) cancer, being (more) understanding of what other people feelb, c
Mental health
Depression/behavioral-emotional control Health distress
• feeling depresseda, b, c
• feeling angry or frustratedb, c
• feeling stressedb, c
• mood swingsb, c
• needing psychological supportb, c
• feeling irritablea, b, c
• feeling upset about having (had) cancerb, c
• fear of recurrence or spread cancerb, c
• worried about healthb, c
• fear of dyingb, c
• fear of new cancerb, c
• fear family members will develop cancerb, c
Anxiety
• being worrieda, b, c
• feeling anxious b, c
Physical symptoms
• altered hair structureb, c
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Table 3 Consolidated issue list with generic survivorship issues (Continued)
• weight gainb, c
• feeling ill or unwellb
• acid refluxb
• overall healtha, b, c
Fatigue Sleep problems
• feeling constantly tiredb, c
• needing more sleep to functionc
• feeling exhaustedb, c
• feeling tireda, b, c
• needing time to recover from normal activitiesc
• feeling weaka, b, c
• needing to take napsb
• sudden attacks of tirednessb, c
• problems falling asleepb, c
• waking up frequently at nightb, c
• trouble sleepinga,b, c
• waking up too earlyb
Physical functioning/ mobility Leg problems
• difficulty carrying something in both hands while climbing stairsb
• difficulty taking a long walka,b, c
• difficulty running fastb, c
• difficulty carrying something weighing 5 kgb, c
• difficulty hiking for 3 kmb, c
• difficulty walking up a flight of stairsb, c
• difficulty doing strenuous activities like carrying a heavy shopping bag or a
suitcasea, b
• difficulty standing for a long timeb, c
• restless legsc
• swollen feet or legsb, c
Pain Skin Problems
• headachesb, c
• joint painc
• muscle painb, c
• dry and or scaly skinb, c
• thin skinb, c
Raynaud Neuropathy
• hands and/or feet sensitive to hot and coldc
• cold or pale fingers or toesb, c
• tingling in hands and/or feetb, c
Muscle problems Temperature
• muscle crampsb, c
• muscle weaknessS
• night sweatsb, c
• hot flushesb, c
• feeling coldb, c
Role functioning
• limited in recreational activitiesa,b, c
Work
• difficulties returning to work since having (had) cancerb, c
• having (had) cancer decreased work performanceb, c
• career interrupted due to cancerb, c
Feelings of belonging
Positive impact Negative impact
• family relationships are close(r) due to having (had) cancerb, c
• having (had) cancer has a positive impact on the relationship with my
partnerb, c
• feeling close(r) to friends since having (had) cancerb, c
• friends and family are (more) important since having (had) cancerb, c
• feeling that others do not understand the impact of having (had)
cancerb, c
• not wanting to burden family membersb, c
• worried about the impact of my cancer on my childrenb, c
Sexual problems
• feeling guilty for not fulfilling sexual needs of partnerb
Sex-specific sexual problems Sexual frequency
• vaginal drynessb, c
• problems getting or maintaining erectionb, c
• low interest in sexb, c
• sexually active with or without intercourseb, c
• avoiding sexb
Sexual pleasure
• difficulty becoming sexually arousedb
• feeling uneasy with sexb
• problems enjoying sexb
• problems having an orgasmb
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cancer on their lives and issues related to struggles with
family and friends as being very relevant; lung, lymphoma,
and colorectal cancer survivors more frequently rated
work-related issues; and bladder and head & neck cancer
survivors more frequently endorsed role functioning
issues. Most of these site-specific survivorship issues
are currently not included in the existing site-specific
modules of the EORTC.
The literature consistently shows that younger cancer
survivors report a higher impact of their cancer experi-
ence on HRQOL [45, 46], including higher levels of dis-
tress, than older cancer survivors. This is likely related to
the fact that relatively younger survivors are confronted
with a life-threatening illness at a time when many are in
the midst of forming relationship bonds, starting and rais-
ing families, and trying to establish a workable balance be-
tween career and family life. During this period of young
adulthood, a serious illness such as cancer is less expected,
and may therefore be more disruptive. Also, younger can-
cer patients and survivors may perceive themselves as hav-
ing more to lose in terms of future perspective, and may
have fewer opportunities for peer support (i.e., having con-
temporaries with whom they can share their common ex-
perience of having had cancer). Conversely older survivors
have more life experience, which might lead to better cop-
ing strategies, and they may face fewer work-related and
social demands. This is supported by the findings from
our study that younger survivors are more likely than
older survivors to rate issues related to having children, fi-
nancial difficulties, loss of future life plans, and lack of
support as being relevant to them. Although some of these
issues appear to be more relevant to younger survivors, in
the interest of parsimony (i.e., not having to create two
versions of a core survivorship questionnaire), we have
decided to include them in our consolidated issue list.
A strength of our study is that we included a relatively
large number of survivors from 11 cancer diagnosis
groups from a total of 14 European countries. This en-
hances the generalizability of our findings. Also, our
strategy with site-specific survivor modules ensures that
relevant chronic physical symptoms are included. Fur-
thermore, the retention of the items and scales of the
QLQ-C30 that are still relevant for disease-free survi-
vors will ensure continuity in the evaluation of HRQOL
over time, from diagnosis through the long-term sur-
vivorship phase.
A possible limitation of our work is that those cancer
survivors in our sample who were more than 5 years
post-treatment were drawn primarily from hospital
registries. Many patients who are 5 years or longer post-
treatment may no longer be in active follow-up, and
those who are may be those with more serious, chronic
health problems. This could cause some degree of over-
estimation of the relevance of various survivorship issues
in this subgroup of longer term survivors. Also, our
sample was somewhat younger than one might expect
based on the median age of the general population at
cancer diagnosis (66 years) [47].
Conclusions
We identified 116 generic survivorship issues, and on
average, 26 site-specific survivorship issues per tumor
site. Compared to existing cancer survivorship question-
naires, our findings underscore the relevance of asses-
sing issues related to chronic physical side effects of
treatment such as neuropathy and joint pain in addition
to the psychosocial aspects of survivorship.
In the next phase of this project, we will further develop
and test the core survivorship questionnaire, and we will
also develop survivorship modules for breast, prostate,
and colorectal cancer survivors. The choice of these three
disease sites was based on the incidence, survival rates,
and the number of survivorship studies conducted in
these disease sites. In the longer term, we intend to
develop survivorship modules for a much broader set of
cancer sites. Ultimately, this will yield a comprehensive
suite of survivorship questionnaires that will yield both a
common data set for comparison of results across tumor
Table 3 Consolidated issue list with generic survivorship issues (Continued)
• problems with sexual intimacyb, c
Sub-analyses: issues relevant to younger cancer survivors
• upset with appearance of scarb, c
• feeling angry towards bodyb, c
• feeling embarrassed about bodyb, c
• concerned about the ability to have childrenb, c
• having problems with people treating me differently because I have (had) cancerb, c
• difficulties talking about cancer b, c
• my personality has changed for the worse due to having (had) cancerb, c
• having (had) cancer has made me lose my future life plans or goalsb
• financial problems caused by problems with getting a loan, mortgage, or insuranceb, c
Issues in this list were endorsed by 30% of the survivors in at least 6 of the included cancer sites
aissues which are also included in the QLQ-C30
bissues identified in the literature
cissues identified in the survivor interviews
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sites, and unique information about the survivorship
experience of specific groups of cancer survivors.
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